Media
Hua Medicine's Dorzagliatin Announces Additional Data to be Presented at CDS 2020
November 26, 2020 – Shanghai, China
Hua Medicine (the"Company", Stock Code: 2552. HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, announced additional analysis results from dorzagliatin’s 24-week metformin combination registration trial DAWN, (also known as HMM0302).
Findings from the DAWN study will be presented in oral and symposium presentations at the Chinese Diabetes Society’s 2020 Scientific Meeting. The 24-week data indicates that, for Type 2 diabetes patients whose blood glucose cannot be controlled with the maximum tolerated dose of metformin (1500mg/day), the dorzagliatin and metformin treatment group lowered HbA1c by 1.02%, superior over placebo treated group by 0.66% (placebo + metformin group reduced HbA1c by 0.36%). Dorzagliatin also demonstrated the below characteristics:
| ● | Fast on-set of action (effective HbA1c reduction in 4 weeks) | |
| ● | Significant improvement of β-cell function and reduction of insulin resistance in treatment group as compared to the placebo group | |
| ● | Significant reduction of 2-hour post-prandial glucose reduction was observed in treatment group as compared to the placebo group | |
| ● | Good safety profile and tolerance of dorzagliatin with limited hypoglycemia (Less than 1% observed during 24-week treatment) | |
| ● | Sustained efficacy over 24 weeks | |
| ● | Good response rate | |
"The analysis of dorzagliatin combination with metformin data continues to support the thesis of dorzagliatin in restoring glucose homeostasis," said Dr. Li Chen, CEO and CSO of Hua Medicine. "The results demonstrate dorzagliatin’s potential in Type 2 diabetes patients who are metformin tolerant and continue to support our efforts to launch dorzagliatin in combination with other existing T2D drugs on the market to better serve the broad patient population."
In addition, dorzagliatin has demonstrated positive clinical results in combination studies with SGLT-2 and DPP-4 inhibitors, significantly enhancing glucose lowering effect.
In the trial, Dorzagliatin exhibits positive impact on blood glucose control.
The analysis of Phase III combination with metformin results shows that dorzagliatin exhibits several promising characteristics for T2D treatment.
| ● | Dorzagliatin combined with metformin treatment group achieved a statistically significant reduction of blood glucose - 1.02% reduction in HbA1c from baseline, as compared to 0.36% in the metformin only group | |
| ● | Dorzagliatin combined with metformin treatment group reached 40% response rate at week 8, and 44.4% at week 24 | |
| ● | Significant 2-hour post-prandial glucose reduction was observed (-5.45mmol/L vs -2.98mmol/L, p<0.0001) | |
| ● | Patients saw fast on-set of blood glucose reduction during the first follow-up visit after initiation of treatment | |
| ● | Hypoglycemia was very mild (less than 1% over 24-week period) | |
| ● | Other incidences of adverse events were similar between the treatment and placebo groups | |
| ● | Through HOMA2-β1 analysis, the dorzagliatin treatment group demonstrated significant β-cell function improvement, with 3.77% increase in the treatment group, versus 1.35% in the placebo group. | |
Note 1：
The HOMA, Homeostatic Model Assessment, is a computer model to evalsuate the beta cell function and insulin resistance in clinical studies that was developed in 1985. It is used to estimate the insulin sensitivity and beta cell function based on fasting glucose and insulin or c-peptide. HOMA2 is a computer model advance from HOMA1 and includes the factors of hepatic and peripheral insulin resistance, a physiological measure of glucose homeostasis.
Diabetes Care 2004, 27(6), 1487
About Dorzagliatin
Dorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive, degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 diabetes. By addressing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired glucose homeostasis state of patients with Type 2 diabetes and serve as a first-line standard-of-care therapy for the treatment of the disease, or as a cornerstone therapy when taken in combination with currently approved anti-diabetes drugs. The Company has completed the Phase III monotherapy registration trial for dorzagliatin, and achieved the primary efficacy endpoint for a second Phase III registration trial for dorzagliatin combined with metformin, and expect to release 52-week data by year end 2020. Hua Medicine has received the drug manufacturing permit for dorzagliatin from the Shanghai Municipal Drug Administrative Bureau, and is preparing for NDA submission to the NMPA, in order to achieve dorzagliatin’s “global first-in-class, launch in China first” goal, to benefit diabetes patients worldwide.
About Hua Medicine
Hua Medicine is a leading, clinical-stage innovative drug development company in China focused on developing novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua Medicine advanced a first-in-class oral drug for the treatment of T2DM into NDA-enabling stage and is currently evalsuating the therapy in adults with diabetes in two Phase III trials in China and various earlier stage clinical trials in China and the United States. Dorzagliatin has achieved its primary endpoint in both of its Phase III monotherapy and combination trials in China over the 24-week trial period, and completed its 52-week Phase III monotherapy trial. The Company has initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine is working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide.
For more information
Hua Medicine
Website：www.czfubang.com
Investors
Email：ir@czfubang.com
Media
Email：pr@czfubang.com
沪ICP备99665955号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
